Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists

OBJECTIVE: Acute myeloid leukemia (AML) is primarily a disease of older adults. These patients may not be candidates for intensive treatment, and there has been an ongoing need for treatment options for this group. We review the use of glasdegib, a hedgehog-pathway inhibitor available for use in com...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Oncol Pharm Pract
Egile Nagusiak: Relias, Valerie, McBride, Ali, Newman, Matthew J, Paul, Shilpa, Saneeymehri, Seyyedeh, Stanislaus, Genique, Tobin, Jennifer, Hoang, Caroline J, Ryan, Joanne C, Galinsky, Ilene
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: SAGE Publications 2020
Gaiak:
Review Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8008421/
https://ncbi.nlm.nih.gov/pubmed/33215562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1078155220973737
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak